Perspective Therapeutics, Inc. (CATX)

Nyse Mkt Llc • Healthcare

$1.61

-$0.64 (-28.8%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$2.4

Day Range$1.58 - $2.4

Avg. Volume (3M)1.8M

Market Cap$183.7M

52 Week Range

$1.58$6.16

Next EarningsIn 16 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$81K100%

Gross Profitminus cost of goods$81K100%

Fundamentals & Financials

Revenue (TTM)

$366K

Net Income (TTM)

-$116.4M

EPS (TTM)

-$1.56

ROA (TTM)

-29.7%

Current Ratio

6.61

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

0.0%Q3 2025-$0.3

-6.1%Q4 2025-$0.35

-37.8%Q1 2026-$0.51

+13.8%Q2 2026-$0.25

+12.4%Q3 2026-$0.22

Nov 9

in 16 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +12.4%

Perspective Therapeutics beat consensus on adjusted EPS in the second fiscal quarter of 2026, reported Aug. 10 based on preliminary results, with adjusted EPS of -$0.22 versus the -$0.25 estimate, about +12% and up from -$0.30 a year ago. Gross profit came in at about $1.1 million, while net income was a loss of about $26.8 million, wider than the $21.5 million loss a year earlier by 24.7%; operating cash flow was negative $20.6 million. Consensus for the next period calls for EPS of -$0.26 on revenue of $89,871.00.

Next report — what to expect

Perspective Therapeutics, Inc. (CATX) is set to report earnings on November 9, 2026. Wall Street expects EPS of -$0.24 on revenue of $62,149.00. For trailing context, revenue fell -72.1% year over year last quarter. CATX has beaten EPS in 3 of 8 most recent quarters.

View full earnings history

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. trades on the NYSE American as CATX and operates in healthcare as a small-cap company focused on cancer treatment technologies. Its offerings span radiopharmaceutical products and medical devices for cancer and other serious malignant conditions, and include CS-1 Cesium-131 brachytherapy seeds.

Name

Perspective Therapeutics, Inc.

CEO

Johan Spoor

Website

www.perspectivetherapeutics.com

Industry

Healthcare

Year Founded

1998

Employees

165

Today's Snapshot

AI-generated

The day ended with CATX 28.8% lower at 1.61, in line with a weaker sector. Shares changed hands at roughly three times its usual level. Perspective Therapeutics reported interim trial results for a treatment targeting neuroendocrine tumors.

Trading Volume

Above 10d avg 1.7M

5.5M

vs S&P 500 Today

Strong Underperformance

-28.24%

Updated: October 23, 2026 at 20:24 UTC

Technical Indicators

2 Buy0 Neutral6 Sell

CATX trades near 1.61 and carries a bearish tilt despite oversold readings on some oscillators. Short-term momentum indicators and MACD are negative, and the stock is clearly below its short-, medium- and 200-day moving averages with the classic pivot also well above the current price, keeping broader structure weak. ATR is relatively high as a percentage of price, highlighting elevated volatility on the downside, and OBV points to selling pressure. Technical takeaway: Sell — momentum and moving-average structure favor further caution despite oversold signals.

All signals

EMA (5 indicators)$2.20 - $3.19
Sell
RSI (14)26.26
Buy
Stochastic %K (14, 3, 3)13.78
Buy
MACD Level (12, 26)-0.21
Sell

Peers & Related Assets

NVCRNovocure Ltd

$14.68-2.8%

ARAYAccuray Incorporated

$0.13-2.9%

DCTHDelcath Systems, Inc.

TLSITriSalus Life Sciences, Inc.

SRTSSensus Healthcare, Inc.

ITOCiTonic Holdings Ltd.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.